S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The Strategic Gold Play You Haven't Heard About (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
The Trade Desk: 3 reasons to buy before a new all-time high
The Strategic Gold Play You Haven't Heard About (Ad)
Rivian shares gets discounted; shares can move lower 
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The Strategic Gold Play You Haven't Heard About (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
The Trade Desk: 3 reasons to buy before a new all-time high
The Strategic Gold Play You Haven't Heard About (Ad)
Rivian shares gets discounted; shares can move lower 
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The Strategic Gold Play You Haven't Heard About (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
The Trade Desk: 3 reasons to buy before a new all-time high
The Strategic Gold Play You Haven't Heard About (Ad)
Rivian shares gets discounted; shares can move lower 
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The Strategic Gold Play You Haven't Heard About (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
The Trade Desk: 3 reasons to buy before a new all-time high
The Strategic Gold Play You Haven't Heard About (Ad)
Rivian shares gets discounted; shares can move lower 
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard

Nektar Therapeutics (NKTR) Short Interest Ratio & Short Volume

$0.64
-0.02 (-2.81%)
(As of 08:59 AM ET)

Nektar Therapeutics Short Interest Data

Current Short Volume
5,800,000 shares
Previous Short Volume
5,440,000 shares
Change Vs. Previous Month
+6.62%
Dollar Volume Sold Short
$3.15 million
Short Interest Ratio / Days to Cover
4.8
Last Record Date
January 31, 2024
Outstanding Shares
190,770,000 shares
Percentage of Shares Shorted
3.04%
Today's Trading Volume
3,486 shares
Average Trading Volume
1,056,043 shares
Today's Volume Vs. Average
0%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Nektar Therapeutics ?

Sign up to receive the latest short interest report for Nektar Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

NKTR Short Interest Over Time

NKTR Days to Cover Over Time

NKTR Percentage of Float Shorted Over Time


Nektar Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
1/31/20245,800,000 shares $3.15 million +6.6%N/A4.8 $0.54
1/15/20245,440,000 shares $2.91 million +1.7%N/A3.7 $0.53
12/31/20235,350,000 shares $3.02 million -23.1%N/A3.4 $0.57
12/15/20236,960,000 shares $3.26 million -3.7%N/A4.5 $0.47
11/30/20237,230,000 shares $3.54 million -9.7%N/A4.6 $0.49
11/15/20238,010,000 shares $4.21 million +7.2%N/A4.7 $0.53
10/31/20237,470,000 shares $3.50 million -8.8%N/A2.8 $0.47
10/15/20238,190,000 shares $4.41 million +5.8%N/A1.4 $0.54
9/30/20237,740,000 shares $4.61 million +6.6%N/A1.3 $0.60
9/15/20237,260,000 shares $5.12 million +7.1%N/A1.2 $0.71
8/31/20236,780,000 shares $4.03 million -5.2%N/A1 $0.60
8/15/20237,150,000 shares $5.79 million +23.3%N/A1 $0.81
7/31/20235,800,000 shares $3.11 million +9.9%N/A0.9 $0.54
7/15/20235,280,000 shares $2.90 million -2.8%N/A1.5 $0.55
6/30/20235,430,000 shares $3.12 million -50.8%N/A1.4 $0.58
6/15/202311,030,000 shares $6.23 million +11.5%N/A2 $0.56
5/31/20239,890,000 shares $5.74 million -2.1%N/A2 $0.58
5/15/202310,100,000 shares $7.71 million +5.4%N/A2 $0.76
4/30/20239,580,000 shares $7.21 million +16.7%5.8%2 $0.75
4/15/20238,210,000 shares $7.60 million -3.5%N/A1.7 $0.93
3/31/20238,510,000 shares $5.98 million +20.2%N/A1.9 $0.70
3/15/20237,080,000 shares $8.07 million -19.1%N/A2.9 $1.14
2/28/20238,750,000 shares $12.08 million -11.8%N/A4.5 $1.38
2/15/20239,920,000 shares $30.85 million -0.1%N/A4.9 $3.11
1/31/20239,930,000 shares $27.01 million +7.7%N/A6.1 $2.72
1/15/20239,220,000 shares $23.23 million +2.4%N/A5.9 $2.52
12/30/20229,000,000 shares $20.34 million -1.6%N/A5.6 $2.26
12/15/20229,150,000 shares $24.71 million -44.4%N/A5.3 $2.70
11/30/202216,470,000 shares $46.12 million -1.9%N/A9 $2.80
11/15/202216,790,000 shares $65.82 million -3.2%N/A10.6 $3.92
10/31/202217,350,000 shares $65.24 million -0.2%N/A10.6 $3.76
10/15/202217,390,000 shares $61.73 million -0.6%N/A9.5 $3.55
9/30/202217,500,000 shares $56 million -0.5%N/A7.7 $3.20
9/15/202217,590,000 shares $64.38 million -0.2%N/A6.5 $3.66
8/31/202217,630,000 shares $69.46 million -6.5%N/A6.1 $3.94
8/15/202218,860,000 shares $92.60 million -0.7%N/A6.1 $4.91
7/31/202219,000,000 shares $75.24 million -19.4%N/A5.7 $3.96
7/15/202223,560,000 shares $84.34 million +17.1%N/A6.6 $3.58
6/30/202220,120,000 shares $76.46 million +14.1%N/A5.2 $3.80
6/15/202217,640,000 shares $59.27 million -1.2%N/A4.4 $3.36













NKTR Short Interest - Frequently Asked Questions

What is Nektar Therapeutics' current short interest?

Short interest is the volume of Nektar Therapeutics shares that have been sold short but have not yet been closed out or covered. As of January 31st, traders have sold 5,800,000 shares of NKTR short. Learn More on Nektar Therapeutics' current short interest.

What is a good short interest ratio for Nektar Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NKTR shares currently have a short interest ratio of 5.0. Learn More on Nektar Therapeutics's short interest ratio.

Which institutional investors are shorting Nektar Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Nektar Therapeutics: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Nektar Therapeutics' short interest increasing or decreasing?

Nektar Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totaling 5,800,000 shares, an increase of 6.6% from the previous total of 5,440,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Nektar Therapeutics' short interest compare to its competitors?

Here is how the short interest of companies in the sector of "medical" compare to Nektar Therapeutics: Assembly Biosciences, Inc. (6.45%), Omeros Co. (22.74%), Oramed Pharmaceuticals Inc. (0.97%), Atossa Therapeutics, Inc. (5.46%), Generation Bio Co. (3.01%), Reviva Pharmaceuticals Holdings, Inc. (3.01%), Anixa Biosciences, Inc. (2.26%), Nuvectis Pharma, Inc. (7.74%), I-Mab (1.95%), Cartesian Therapeutics, Inc. (5.97%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.48 billion), General Motors ($3.85 billion), Charter Communications, Inc. ($3.38 billion), Occidental Petroleum Co. ($3.00 billion), Super Micro Computer, Inc. ($2.66 billion), Tractor Supply ($2.37 billion), Coinbase Global, Inc. ($2.25 billion), Moderna, Inc. ($2.11 billion), Royal Caribbean Cruises Ltd. ($2.06 billion), and Floor & Decor Holdings, Inc. ($1.67 billion). View all of the most shorted stocks.

What does it mean to sell short Nektar Therapeutics stock?

Short selling NKTR is an investing strategy that aims to generate trading profit from Nektar Therapeutics as its price is falling. NKTR shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Nektar Therapeutics?

A short squeeze for Nektar Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NKTR, which in turn drives the price of the stock up even further.

How often is Nektar Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NKTR, twice per month. The most recent reporting period available is January, 31 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:NKTR) was last updated on 2/23/2024 by MarketBeat.com Staff